Oligodendrocyte precursor cells as a therapeutic target for demyelinating diseases
ReviewHumansOther animals
- Design
- Review
- Subjects
- Not stated in the abstract
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Why remyelination fails and what drug targets might restore it: oligodendrocyte precursor cell biology, myelination and pharmacological targets in diseases such as multiple sclerosis, including nanoscale delivery
What the authors reported
This discusses why remyelination fails with age and in multiple sclerosis, and possible drug targets for promoting precursor cell differentiation. The abstract does not mention palmitoylethanolamide.
Limits of this study
A narrative review; the abstract contains no palmitoylethanolamide data, so any PEA content lies in the full text. Funding and conflicts not stated in the abstract.
Source
PubMed 30961866 · doi:10.1016/bs.pbr.2019.03.013
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.